Nuvectis Pharma (NVCT)
(Delayed Data from NSDQ)
$6.46 USD
+0.16 (2.54%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $6.54 +0.08 (1.24%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Brokerage Reports
Nuvectis Pharma, Inc. [NVCT]
Reports for Purchase
Showing records 1 - 20 ( 68 total )
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Oncology Asset Duo Continue to Advance; Several Clinical Updates Expected in 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q24: Informative Clinical Data Coming Over 2024 For NXP800 And NXP900
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
AACR Unveils NXP900 Potential to Reverse Treatment Resistances in NSCLC Models; Clinical Progress of NXPs Ongoing
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase 1b NXP800 Efficacy in Platinum-Resistant ARID1a-Mutant OC
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
4Q23: Imminent Preliminary NXP800 Phase 1b Data, NXP900 In Phase 1a
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology and Medical Device Conference Note
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Collaborates with Mayo Clinic to Evaluate NXP800 in Cholangiocarcinoma
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for NVCT 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data Underscore NXP800''s Utility In ARID1A 1B Mutant Tumors
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
3Q23: NXP800 In Phase 1b, NXP900 In Phase 1a, Funded Into Early 2025
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
KOL Insights Reinforce the Case for NXP800 and NXP900 in Oncology; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2Q23: NXP800 In Phase 1b, NXP900 Phase 1 Starts in 3Q23, Funded Into 1H25
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J